Associated Genetic Biomarkers
ATM P2699L serves as an inclusion eligibility criterion in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials that contain ATM P2699L as an inclusion criterion, 1 is phase 1 (1 open) and 2 are phase 2 (2 open).
Trials with ATM P2699L in the inclusion eligibility criteria most commonly target bladder carcinoma, malignant solid tumor, small cell lung carcinoma, and urothelial carcinoma .
Olaparib and vx-803 are the most frequent therapies in trials with ATM P2699L as an inclusion criteria .
Significance of ATM P2699L in Diseases
Bladder Carcinoma +
Malignant Solid Tumor +
Ovarian Serous Tumor +
Small Cell Lung Carcinoma +
ATM is altered in 3.05% of small cell lung carcinoma patients .
ATM P2699L is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM P2699L and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
Urothelial Carcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.